GENAISSANCE PHARMACEUTICALS INC
10-Q, EX-27, 2000-09-01
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: GENAISSANCE PHARMACEUTICALS INC, 10-Q, 2000-09-01
Next: BENNION CORP, 8-K, 2000-09-01



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>                     <C>                     <C>
<PERIOD-TYPE>                   12-MOS                   6-MOS                  6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999             DEC-31-2000             DEC-31-1999
<PERIOD-START>                             JAN-01-1999             JAN-01-2000             JAN-01-1999
<PERIOD-END>                               DEC-31-1999             JUN-30-2000             JUN-30-1999
<CASH>                                           3,666                  28,025                       0
<SECURITIES>                                         0                  19,112                       0
<RECEIVABLES>                                        0                       0                       0
<ALLOWANCES>                                         0                       0                       0
<INVENTORY>                                          0                       0                       0
<CURRENT-ASSETS>                                 3,872                  47,631                       0
<PP&E>                                               0                       0                       0
<DEPRECIATION>                                       0                       0                       0
<TOTAL-ASSETS>                                  11,514                  62,412                       0
<CURRENT-LIABILITIES>                            3,528                   4,755                       0
<BONDS>                                              0                       0                       0
                           11,247                  68,519                       0
                                          0                       0                       0
<COMMON>                                             3                       3                       0
<OTHER-SE>                                    (14,835)                (27,798)                       0
<TOTAL-LIABILITY-AND-EQUITY>                    11,514                  62,412                       0
<SALES>                                              0                       0                       0
<TOTAL-REVENUES>                                     0                     120                     556
<CGS>                                                0                       0                       0
<TOTAL-COSTS>                                        0                       0                       0
<OTHER-EXPENSES>                                     0                  15,948                   3,462
<LOSS-PROVISION>                                     0                       0                       0
<INTEREST-EXPENSE>                                   0                     957                     223
<INCOME-PRETAX>                                      0                       0                       0
<INCOME-TAX>                                         0                       0                       0
<INCOME-CONTINUING>                                  0                (15,628)                 (2,973)
<DISCONTINUED>                                       0                       0                       0
<EXTRAORDINARY>                                      0                       0                       0
<CHANGES>                                            0                       0                       0
<NET-INCOME>                                         0                (70,532)                 (4,014)
<EPS-BASIC>                                          0                 (25.05)                  (1.47)
<EPS-DILUTED>                                        0                       0                       0


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission